Dec 06 2023 17 mins
Cementing the role of adjuvant osimertinib in NSCLC
The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC.
We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.
For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates.